Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Otis W. Brawley"'
Autor:
Otis W. Brawley, Jeromie Ballreich, Lin Wang, Hwanhee Hong, Channing J. Paller, G. Caleb Alexander
Publikováno v:
Value Health
Objectives To assess the cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer from the US healthcare sector perspective with a lifetime horizon. Methods We built a partitioned survival model based on a network
Autor:
Anthony De Felice, Lin Wang, Hwanhee Hong, G. Caleb Alexander, Channing J. Paller, Otis W. Brawley
Publikováno v:
JAMA Oncol
Importance Multiple systemic treatments are available for metastatic castration-sensitive prostate cancer (mCSPC), with unclear comparative effectiveness and safety and widely varied costs. Objective To compare the effectiveness and safety determined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17e5d83ae2989adcbf2736fe61e7beed
https://europepmc.org/articles/PMC7809610/
https://europepmc.org/articles/PMC7809610/
Autor:
Otis W. Brawley
Publikováno v:
Urologic Clinics of North America. 30:331-335
Given that no therapy for localized prostate cancer has been proven superior to any other in well-designed clinical trials, the patient and physician may be influenced toward a particular therapy by a number of nonmedical factors. These factors can b
Autor:
Patricia Davis, David J. Liewehr, David R. Kohler, William D. Figg, Toni Wells-jones, William L. Dahut, Nehal Lakhani, Eddie Reed, Seth M. Steinberg, Otis W. Brawley, Michael Hamilton, Paul H. Duray
Publikováno v:
Acta Oncologica. 42:195-201
In this phase I/II clinical trial the antitumor activity of high-dose tamoxifen when administered in combination with vinblastine was assessed and the toxicity profile of this combination characterized. All 25 patients enrolled in this study were req
Autor:
Otis W. Brawley, Edward L. Trimble, Richard Ungerleider, M Smith, Nancy Breen, Warren B. Sateren, Leslie G. Ford, Jeffrey Abrams, Mary S. McCabe, Michaele C. Christian, Richard Kaplan
Publikováno v:
Journal of Clinical Oncology. 20:2109-2117
PURPOSE: We chose to examine the impact of socioeconomic factors on accrual to National Cancer Institute (NCI)–sponsored cancer treatment trials. PATIENTS AND METHODS: We estimated the geographic and demographic cancer burden in the United States a
Publikováno v:
Prostate Cancer Prevention ISBN: 9783642451942
Chemoprevention refers to the use of pharmacologic interventions to delay, prevent, or reverse carcinogenesis with the ultimate goal of reducing cancer incidence. Two large, population-based, phase 3 prostate cancer prevention trials reported that 5-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ac636461af5f3dedf25b9a9a19dce0b
https://doi.org/10.1007/978-3-642-45195-9_9
https://doi.org/10.1007/978-3-642-45195-9_9
Autor:
Polly Feigl, Otis W. Brawley, John Crowley, Brent A. Blumenstein, Charles A. Coltman, Ian M. Thompson, Barnett S. Kramer, Michael Wolf, Leslie G. Ford
Publikováno v:
Controlled Clinical Trials. 16:150-163
The PCPT is a chemoprevention trial of finasteride with a primary endpoint of biopsy-proven presence or absence of prostate cancer. A total of 18,000 healthy men, aged 55 years and older, will be randomized. Half will receive finasteride (5 mg/day) a
Autor:
Richard B. Warnecke, Paul A. Godley, Dan Garson-angert, Arnold D. Kaluzny, Otis W. Brawley, James E. Shaw, Leslie G. Ford
Publikováno v:
JNCI Journal of the National Cancer Institute. 85:1945-1950
Background The Minority-Based Community Clinical Oncology Program (MBCCOP) was initiated in September 1990 to expand the National Cancer Institute's (NCI's) clinical trials network to minority populations. Institutions, organizations, and/or physicia
Autor:
Otis W. Brawley
Publikováno v:
Controlled Clinical Trials. 16:293-295
Autor:
Otis W. Brawley
Publikováno v:
Oncology Issues. 10:22-24